The Dangers of Using Cq to Quantify Nucleic Acid in Biological Samples: A Lesson From COVID-19. (22nd October 2021)
- Record Type:
- Journal Article
- Title:
- The Dangers of Using Cq to Quantify Nucleic Acid in Biological Samples: A Lesson From COVID-19. (22nd October 2021)
- Main Title:
- The Dangers of Using Cq to Quantify Nucleic Acid in Biological Samples: A Lesson From COVID-19
- Authors:
- Evans, Daniel
Cowen, Simon
Kammel, Martin
O'Sullivan, Denise M
Stewart, Graham
Grunert, Hans-Peter
Moran-Gilad, Jacob
Verwilt, Jasper
In, Jiwon
Vandesompele, Jo
Harris, Kathryn
Hong, Ki Ho
Storey, Nathaniel
Hingley-Wilson, Suzie
Dühring, Ulf
Bae, Young-Kyung
Foy, Carole A
Braybrook, Julian
Zeichhardt, Heinz
Huggett, Jim F - Abstract:
- Abstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA quantities, measured by reverse transcription quantitative PCR (RT-qPCR), have been proposed to stratify clinical risk or determine analytical performance targets. We investigated reproducibility and how setting diagnostic cutoffs altered the clinical sensitivity of coronavirus disease 2019 (COVID-19) testing. Methods: Quantitative SARS-CoV-2 RNA distributions [quantification cycle (Cq) and copies/mL] from more than 6000 patients from 3 clinical laboratories in United Kingdom, Belgium, and the Republic of Korea were analyzed. Impact of Cq cutoffs on clinical sensitivity was assessed. The June/July 2020 INSTAND external quality assessment scheme SARS-CoV-2 materials were used to estimate laboratory reported copies/mL and to estimate the variation in copies/mL for a given Cq. Results: When the WHO-suggested Cq cutoff of 25 was applied, the clinical sensitivity dropped to about 16%. Clinical sensitivity also dropped to about 27% when a simulated limit of detection of 10 6 copies/mL was applied. The interlaboratory variation for a given Cq value was >1000 fold in copies/mL (99% CI). Conclusion: While RT-qPCR has been instrumental in the response to COVID-19, we recommend Cq (cycle threshold or crossing point) values not be used to set clinical cutoffs or diagnostic performance targets due to poor interlaboratory reproducibility; calibrated copy-based units (used elsewhere in virology) offerAbstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA quantities, measured by reverse transcription quantitative PCR (RT-qPCR), have been proposed to stratify clinical risk or determine analytical performance targets. We investigated reproducibility and how setting diagnostic cutoffs altered the clinical sensitivity of coronavirus disease 2019 (COVID-19) testing. Methods: Quantitative SARS-CoV-2 RNA distributions [quantification cycle (Cq) and copies/mL] from more than 6000 patients from 3 clinical laboratories in United Kingdom, Belgium, and the Republic of Korea were analyzed. Impact of Cq cutoffs on clinical sensitivity was assessed. The June/July 2020 INSTAND external quality assessment scheme SARS-CoV-2 materials were used to estimate laboratory reported copies/mL and to estimate the variation in copies/mL for a given Cq. Results: When the WHO-suggested Cq cutoff of 25 was applied, the clinical sensitivity dropped to about 16%. Clinical sensitivity also dropped to about 27% when a simulated limit of detection of 10 6 copies/mL was applied. The interlaboratory variation for a given Cq value was >1000 fold in copies/mL (99% CI). Conclusion: While RT-qPCR has been instrumental in the response to COVID-19, we recommend Cq (cycle threshold or crossing point) values not be used to set clinical cutoffs or diagnostic performance targets due to poor interlaboratory reproducibility; calibrated copy-based units (used elsewhere in virology) offer more reproducible alternatives. We also report a phenomenon where diagnostic performance may change relative to the effective reproduction number. Our findings indicate that the disparities between patient populations across time are an important consideration when evaluating or deploying diagnostic tests. This is especially relevant to the emergency situation of an evolving pandemic. … (more)
- Is Part Of:
- Clinical chemistry. Volume 68:Number 1(2022)
- Journal:
- Clinical chemistry
- Issue:
- Volume 68:Number 1(2022)
- Issue Display:
- Volume 68, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 68
- Issue:
- 1
- Issue Sort Value:
- 2022-0068-0001-0000
- Page Start:
- 153
- Page End:
- 162
- Publication Date:
- 2021-10-22
- Subjects:
- SARS-CoV-2 -- RT-qPCR -- quantification cycle -- cycle threshold
Clinical chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
Biochimie -- Périodiques
Diagnostics biologiques -- Périodiques
Biochemistry
Clinical chemistry
Pharmaceutical chemistry
Biochemistry
Laboratory Techniques and Procedures
Klinische chemie
Periodicals
616.075605 - Journal URLs:
- http://www.oxfordjournals.org/ ↗
https://academic.oup.com/clinchem ↗
http://catalog.hathitrust.org/api/volumes/oclc/1554929.html ↗
http://www.clinchem.org/ ↗ - DOI:
- 10.1093/clinchem/hvab219 ↗
- Languages:
- English
- ISSNs:
- 0009-9147
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25367.xml